|Dr. Chad A. Mirkin Ph.D.||Co-Founder & Director||165k||N/A||1964|
|Dr. David A. Giljohann||CEO, Interim Principal Financial Officer, Corp. Sec. & Director||785.46k||N/A||1981|
|Dr. Matthias G. Schroff Ph.D.||Chief Operating Officer||476.31k||N/A||1968|
|Dr. Douglas E. Feltner||Chief Medical Officer||N/A||N/A||N/A|
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 9.